Bio-Rad Laboratories, a global leader in life science research and clinical diagnostic products, today expanded its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of eight antibodies specific for romozumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isacuximab (Sarclisa), and nilsevimab. (Beyfortus), and tremelimumab (Imjudo), and released a recombinant monoclonal antibiotic therapy antibody specific for dulaglutide (Trulicity). The company also launched the first series of anti-Fc mutant antibodies targeting drugs containing YTE mutations.
Bio-Rad anti-idiotype antibodies.
Image credit: Bio-Rad Laboratories, Inc.
Bio-Rad’s series of highly specific, high-affinity, non-animal-derived antibodies are suitable for use in preclinical and clinical pharmacokinetic (PK) and anti-drug antibody (ADA) assays to support therapeutic drug monitoring of biologic and biosimilar products. The addition of a dulaglutide-specific antibody marks Bio-Rad’s first antibody against a GLP-1 receptor agonist.
The launch of a series of anti-Fc mutant antibodies enables selective detection of YTE-modified therapeutics through recognition of the YTE triple substitution (M252Y, S254T, and T256E) in the Fc region of human IgG1 antibodies. This modification has been shown to increase the half-life of the antibody compared to wild-type IgG. The ready-made antibodies are suitable for the development of PK bridging ELISAs to measure free drug concentrations in serum.
With over 350 antibodies with over 50 different specificities, Bio-Rad’s leading portfolio of monoclonal anti-idiotypic antibodies provides researchers with greater flexibility to develop selective, sensitive, and reliable bioanalytical assays. The launch of our first anti-Fc mutant series alongside a new range of antibiotic therapy antibodies, including our first for drugs that act as GLP-1 receptor agonists, highlights an important step beyond classic anti-ID. Learn how our technology can be adapted to new drug formats and our commitment to driving innovation across antibody drug discovery. ”
Hilary Mavor, Marketing Director, Life Sciences Group, Bio-Rad Research Institute
sauce:
Bio-Rad Laboratories, Inc.
